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Abstract
The CD4 binding site (CD4bs) on the envelope glycoprotein is a major site of vulnerability
that is conserved among different HIV-1 isolates. Many broadly neutralizing antibodies
(bNAbs) to the CD4bs belong to the VRC01 class, sharing highly restricted origins, recogni-
tion mechanisms and viral escape pathways. We sought to isolate new anti-CD4bs bNAbs
with different origins and mechanisms of action. Using a gp120 2CC core as bait, we iso-
lated antibodies encoded by IGVH3-21 and IGVL3-1 genes with long CDRH3s that depend
on the presence of the N-linked glycan at position-276 for activity. This binding mode is simi-
lar to the previously identified antibody HJ16, however the new antibodies identified herein
are more potent and broad. The most potent variant, 179NC75, had a geometric mean IC80
value of 0.42 μg/ml against 120 Tier-2 HIV-1 pseudoviruses in the TZM.bl assay. Although
this group of CD4bs glycan-dependent antibodies can be broadly and potently neutralizing
in vitro, their in vivo activity has not been tested to date. Here, we report that 179NC75 is
highly active when administered to HIV-1-infected humanized mice, where it selects for
escape variants that lack a glycan site at position-276. The same glycan was absent from
the virus isolated from the 179NC75 donor, implying that the antibody also exerts selection
pressure in humans.
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Author Summary
CD4bs is a central viral vulnerability site and isolation of new anti-HIV-1 CD4bs broadly
neutralizing antibodies (bNAbs) provides information about viral escape mechanisms.
Here we describe a new anti-HIV-1 bNAb that was isolated from an HIV-1 infected
donor. The antibody, 179NC75, targets the CD4 binding site in a glycan-dependent man-
ner. Although many CD4bs antibodies have been already described, a glycan-dependent
mode of recognition is unusual for anti-HIV-1 CD4bs bNAbs. The glycan-dependent
CD4bs antibodies have never been tested for their ability to neutralize HIV-1 in vivo. We
infected humanized mice with HIV-1YU2 and treated them with 179NC75 three weeks
after infection. We observed a drop in viral load immediately after treatment followed by a
viral rebound. The viral rebound was associated with specific escape mutations in the
plasma virus envelope, resulting in a deletion of N276 glycan, and in some cases a glycan
shift from position 276 to position 460. Similar signature mutations were found in the
envelope of the autologous virus cloned from patient’s plasma. This defines the escape
pathways from 179NC75, and shows that they are the same in humans and in HIV-1YU2
infected humanized mice.
Introduction
Although the envelope glycoproteins (Env) of primate immunodeficiency viruses have
extremely variable sequences [1], most of them engage CD4 as the primary cellular receptor to
initiate the viral life cycle [2]. The consequence is that the CD4 binding site (CD4bs) is a com-
paratively well-conserved region of Env that serves as a critical neutralization epitope and an
appealing vaccine target. The introduction of single cell antibody cloning techniques [3,4]
yielded dozens of broad and potent CD4bs antibodies from infected individuals, some of which
neutralize ~90% of HIV-1 strains in vitro [5–7]. Some of these antibodies are also effective at
reducing viral load when used to treat infected humanized mice (hu-mice) [8], macaques [9–
11] and humans [12].
The most potent group of CD4bs antibodies characterized to date is derived from two VH
genes, IGVH1-2 [5,7,13] and IGVH1-46 [6,7,14–16]. These antibodies engage many of the
same Env residues as CD4. For example, residue Arg71HC in VRC01-like bNAbs interacts with
residue Asp368gp120 on Env, and thereby mimics how Arg59CD4 interacts with the same residue
when CD4 binds to gp120 [6,7,13,16]. Although the light chains are less restricted in their ori-
gin, specific alterations are required for activity, including mutations and deletions [6,13,16].
Overall, the restricted origins and complex development of these bNAbs from their inactive
germline precursors may explain why it has been so difficult to elicit them by vaccination.
A second, far more diverse group of CD4bs-directed antibodies is often referred to as
‘CDRH3-dominated class of CD4bs antibodies’. These antibodies use their CDRH3-loop
regions to engage Env [15]. These include b12 [17], HJ16 [18], CH103 [19] and the recently
described VRC13 and VRC16 [15]. Structural analyses indicate that all CDRH3-dominated
antibodies use loop-based recognition mechanisms, with the CDRH3 contributing 50%-70% of
the paratope interface [15,19,20]. They are not VH-restricted since their CDRH3s are ran-
domly assembled from IgH variable, diversity and joining segments during V(D)J recombina-
tion [21]. In keeping with their diverse origins, CDRH3-dominated antibodies seem to employ
different mechanisms of recognition and they also vary in the angles with which they approach
the CD4bs [15].
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To isolate new CD4bs bNAbs, we sought HIV-1 infected donors whose sera contained
potent neutralizing antibodies that appeared to target the CD4bs. One such donor was EB179.
By sorting peripheral blood mononuclear cells (PBMCs) from this individual we isolated a new
antibody, 179NC75, that is encoded by IGVH3-21 and IGVL3-1 gene segments. In TZM.bl
neutralization assays 179NC75 showed an overall IC80 of 0.42 μg/ml against 120 Tier-2 HIV-1.
Binding assays using various Env-based proteins indicated that 179NC75 is glycan-depen-
dent and belongs to the same sub-class of CDRH3-dominated CD4bs antibodies as HJ16.
These glycan-dependent CD4bs antibodies have not yet been tested for activity in vivo. To do
so we treated humanized mice infected with HIV-1YU2 with 179NC75 and found that it selects
for escape variants with mutations in the potential N-linked glycosylation site at gp120 position
276. Similar mutations were also found in the autologous isolate from the 179NC75 donor,
suggesting that selection pressure had been exerted in the human host.
Materials and Methods
Ethics statement
For the human studies, The Rockefeller University Institutional Review Board approved all
studies involving patient enrollment, sample collection, and clinical follow-up. Donor EB179
was selected from a group of long-term non- progressors that was followed at the Ragon Insti-
tute in Boston, and is also referred to as subject 330183. The subject described in this study pro-
vided written informed consent prior to participating in this study. For the mouse studies, this
study was carried out in strict accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved
by the Institutional Animal Care and Use Committee (IACUC) of The Rockefeller University,
and in accordance with established guidelines and policies at The Rockefeller University (pro-
tocol number 13618-H).
HIV-1-infected subjects
Purified IgG samples from 394 HIV-1-infected long-term non-progressors were screened for
neutralizing activity against a panel of 14 viruses representing 8 different clades or inter-clade
recombinants. IgG purified from donor EB179 was exceptional in its neutralization potency
and breadth, ranking within the top 2% of the cohort, and neutralized 11 out of the 14 viruses
in the panel (S1A Table). A single leukapheresis sample was obtained 4.5 years after initial
diagnosis with clade B HIV-1 infection, at age 44. At the time the sample was collected, donor
EB179 had 1038 CD4 T cells/mm3 and a viral load of 3180 copies/ml and was not receiving
antiretroviral therapy. Molecular HLA typing revealed HLA A02:01, 68:02; B07:02, 53:01;
Cw04:01, 07:02; DRB11:01, 15:01.
Single B cell sorting and antibody cloning
Single-cell sorting of 2CC core+CD19+IgG+ B cells from donor EB179’s PBMCs was conducted
as previously described [3]. Briefly, we sorted memory B cells using the gp120 2CC core protein
as bait [22]. Rescue primers were used to amplify both heavy chains [7] and Igλ genes [23]. All
PCR products were sequenced and analyzed for Ig gene usage, CDR3, and the number of VH/
VL somatic hypermutations (IgBLAST, http://www.ncbi.nlm.nih.gov/igblast/ and IMGT,
http://www.imgt.org/). Multiple sequence alignments were performed using the MacVector
program (v.13.5.5) with the ClustalW analysis function (default parameters), and then used to
generate dendrograms by the neighbor-joining method (with best tree mode and outgroup
rooting). To specifically isolate members of the 179NC75 clone we used the following forward
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primers for the heavy chains: 5’-CTGCAACCGGTGTACATTCTGAAATGAGATTGGAA
GAAT-3’ and 5’-CTGCAACCGGTGTACATTCTGAGGTCCAGTGTGAAGAA-3’ (in a 1:1
mix); and for the light chains: 5’-ATGGCCTGGATCCCTCTACTTCTC-3’ and 5’- ATGGCA
TGGATCCCTCTCTTCCTC-3’ (in a 1:1 mix). The reverse primers were the same as described
previously for Ig gene amplification [7].
Antibody production
Purified, digested PCR products were cloned into human Igγ1-, IgK or Igλ-expression vectors
as previously described [24]. Antibodies were produced by transient transfection of IgH, IgK
and IgL expression plasmids into exponentially growing HEK 293T cells (ATCC; CRL-11268)
using polyethyleneimine (PEI)-precipitation [24]. IgG antibodies were affinity purified using
Protein G Sepharose beads according to the manufacturer’s instructions (GE Healthcare).
ELISAs
High-binding 96-well ELISA plates (Costar) were coated overnight with 5 μg/ml of purified
2CC core, gp120.YU2 (wild type or mutants) or gp140.YU2 foldon trimer in PBS. After wash-
ing 6 times with PBS + 0.05% Tween 20, the plates were blocked for 2 h with 2% BSA, 1 μM
EDTA and 0.05% Tween-PBS (“blocking buffer”), and then incubated for 1 h with IgGs that
were added as seven consecutive 1:4 dilutions in PBS from an initial concentration of 4 μg/ml.
After additional washing, the plates were developed by incubation with goat HRP-conjugated
anti-human IgG antibodies (Jackson ImmunoResearch) (at 0.8 μg/ml in blocking buffer) for 1
h followed by HRP chromogenic substrate (ABTS solution; Invitrogen). For competition ELI-
SAs, the plates were coated with 5 μg/ml 2CC core, gp120 or gp140 foldon, washed, blocked for
2 h with blocking buffer and then incubated for 1 h with IgGs added as seven consecutive 1:4
dilutions in PBS from an initial concentration of 32 μg/ml, and in the presence of biotinylated
179NC75 antibody at a constant concentration of 4 μg/ml. The plates were then developed
using HRP-congugated streptavidin (Jackson ImmunoReseach) (at 1 μg/ml in blocking buffer).
For ELISAs using BG505 SOSIP.664-D7324 trimers, the plates were coated overnight with
5 μg/ml of D7324 antibody as previously described [25], washed and then incubated with 500
ng/ml of the trimer [25,26]. After a further wash, IgGs were added for 1 h as seven consecutive
1:4 dilutions in PBS from initial concentrations of 4 μg/ml. The endpoint was generated by
incubation with goat HRP-conjugated anti-human IgG antibodies, as described above. All
experiments were performed at least 3 times.
For EndoH ELISA, the plates were coated overnight at 4°C with 5 μg/ml of EndoH-treated
or untreated gp120 in 100 mM sodium bicarbonate/carbonate buffer, pH 9.6. They were then
washed with TBS + 0.05% Tween 20 and blocked for 1 h in the same buffer supplemented with
3% (w/v) BSA, and washed again before test antibodies were added for 2 h. After a final wash,
the endpoint was generated using goat HRP-conjugated anti-human IgG antibodies, again as
described above.
Neutralization assay
HIV-1 neutralization was evaluated using the luciferase-based TZM.bl cell assay as described
previously [27]. Briefly, envelope pseudoviruses were incubated with fivefold serial dilutions of
single antibodies and applied to TZM.bl cells that carry a luciferase-reporter gene. After 48 h
cells were lysed and luminescence was measured. IC50 and IC80 reflect single antibody concen-
trations that caused a reduction in relative luminescence units (RLU) by 50% and 80%,
respectively.
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Humanized mice (hu-mice)
NOD Rag1−/−Il2rgnull (NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ) mice were purchased from The
Jackson Laboratory and bred and maintained at the Comparative Bioscience Center of The
Rockefeller University according to guidelines established by the University’s Institutional Ani-
mal Care and Use Committee. All experiments were performed under protocols approved by
the same committee. Hu-mice were treated with 1 mg of 179NC75 sub-cutaneously (s.c.) on
day 0, followed by 0.5 mg s.c. injections twice-weekly for a period of 5 weeks [8]. The gp120
sequences from escape variant viruses were obtained as previously described [8].
Virus cloning and virus co-culture
The autologous virus from donor EB179 was isolated as previously described [28]. Briefly,
CD19 and CD8-depleted mononuclear cells were cultured at a concentration of 5 × 106 cells/
ml in Iscove's modified Dulbecco’s medium (IMDM; Gibco) supplemented with 10% fetal
bovine serum (FBS; HyClone, Thermo Scientific), 1% GlutaMAX (Gibco), 1% penicillin/strep-
tomycin (Gibco), and 1 μg/ml phytohaemagglutinin (Life Technologies) at 37°C and in an
atmosphere containing 5% CO2. After 2–3 days, 5 × 10
6 cells were transferred into IMDM sup-
plemented with 10% FBS, 1% penicillin/streptomycin, 5 μg/ml polybrene (Sigma), and 100 IU/
ml of IL-2. The medium was replaced weekly and the HIV-1 content of culture supernatants
was quantified using the Lenti-X p24 Rapid Titer Kit (Clontech) according to the manufactur-
er’s instructions. Env genes from the autologous virus were cloned by reverse transcriptase
PCR as described elsewhere [29].
HIV-1YU2 envelope mutants
Single, double and triple mutations were introduced into wild-type HIV-1YU2 envelope using
the QuikChange (multi-) site-directed mutagenesis kit, according to the manufacturer’s specifi-
cations (Agilent Technologies).
Results
Serologic specificity
Polyclonal IgG purified from donor EB179 had exceptional neutralization capacity, with
respect of potency and activity against 11 of 14 Tier-2 viruses in a small cross-clade panel (S1A
Table). To map the predominant NAb specificities, we tested EB179 IgG against HIV-1YU2
mutants that are resistant to NAbs targeting the trimer apex (N160K), the CD4bs (N280Y) or
the base of the V3 loop (N332K) [8,30–32]. Among these mutants, only HIVYU2N280Y was
resistant to EB179 IgG (S1B Table). We conclude that at least a proportion of the neutralization
activity present in this serum is directed to the CD4bs.
EB179 CD4bs antibody repertoire
To isolate and characterize the NAbs present in EB179, we used flow cytometry to sort memory
B cells that bound to 2CC core, a gp120 antigen that presents the CD4bs in an exposed and sta-
ble conformation [22]. Among CD19+IgG+ B cells, ~0.2% bound strongly to 2CC core. Of the
372 cells sorted, 87 produced paired heavy and light chains, 36 of which represented ten clon-
ally related families (Fig 1A). Antibody sequences obtained from the expanded B cell clones
contained higher numbers of somatic mutations compared to antibodies obtained from B cells
that appeared only once (S1 Fig). The average number of nucleotide mutations in the heavy
chain of clonal sequences was 44.76 (± 3.66, N = 36) compared to 20.82 (± 1.39 N = 51) for
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unique sequences (S1A Fig). A similar trend was observed when the light chain sequences were
analyzed (S1B Fig).
Representative variants from each of the clonal families were selected for further analysis
(S2 Table). These variants were expressed as IgG1 antibodies that were tested for binding to a
HIV-1YU2 gp140 foldon protein [33] or 2CC core [22], and for neutralizing activity. Except for
179NC9055, all the antibodies bound strongly to the HIV-1YU2 gp140 and/or 2CC core pro-
teins (Fig 1B), and members of clones 1, 2, 3, 4, 6, and 7 neutralized the Tier-1 (i.e., neutraliza-
tion-sensitive) HIV-1BAL virus (Fig 1C). While antibodies from clones 3 and 7 were only
weakly active against the other viruses in the panel, one representative of the most expanded
clone 1 (179NC75) strongly neutralized four of the five viruses tested (IC500.05 μg/ml,
Fig 1C).
Fig 1. 2CC core antibody repertoire in patient EB179. (A) Pie chart representing ten antibody sequence families sorted using the 2CC core protein as bait.
The number in the center of the pie denotes the number of antibodies; slices are proportional to clone size (i.e., frequency) and represent unique clones. The
assigned number of each clone is given next to the corresponding slice on the pie chart. The membership of an antibody in a B cell clone is determined by
sequence analysis, in particular of the CDR3s and shared V and J genes of paired heavy and light chain genes (see Methods). (B) Representative variants of
each clonal family of sequences were expressed and tested in ELISA for binding to 2CC core and gp140 foldon proteins. The numbers in parentheses
correspond to the number of the clone as shown in (A). (C) The table summarizes the different antibodies expressed, the clone they represent and their
binding to 2CC core or gp140 YU2 foldon (based on (B)) and their in vitro neutralization IC50 values, as measured in the TZM.bl cell assay.
doi:10.1371/journal.ppat.1005238.g001
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179NC75 and its clonal relatives
To isolate additional 179NC75 variants, we amplified cDNA from the 2CC core+CD19+IgG+
single-sorted B cells using specific VH and VL forward primers (see Methods). We obtained a
total of 23 heavy chain and 25 light chain variants from the 179NC75 clonal family. The heavy
and light chain sequences carried 34% and 29% amino acid mutations on average, respectively,
compared to their germline gene segments IGVH3-21 and IGVL3-1. The various sequences of
the 179NC75 clone were similar by up to 73% from clonal members (Fig 2A and 2B). The
CDRH3 and CDRL3 regions were 24 and 10 residues long, respectively (Fig 2A and 2B, S2
Table). There were no insertions or deletions.
Variants 179NC 54, 60, 65, 75, 21 and 1055 (indicated in Fig 2A and 2B) were tested for
activity against a panel of nine Tier-2 viruses, including three from clade B, one from clade C,
two from clade A, two clade A/G recombinants and one clade A/E recombinant. 179NC75 and
two closely related variants, 179NC54 and 179NC60, potently neutralized 6 of these 9 viruses,
whereas the other antibodies had lesser or no neutralization activity (Fig 2C). Accordingly, we
selected 179NC75 for additional analyses.
When tested against an extended cross-clade panel of 120 Tier-2 viruses, 179NC75 neutral-
ized viruses from clades B particularly strongly (S3 Table); its geometric mean IC50 and IC80
values were 0.113 μg/ml and 0.291 μg/ml, respectively (S4 Table). When compared to other
CD4bs bNAbs against a panel of 22 Tier-2 clade, B viruses, 179NC75 was more potent than
b12 against 13 viruses, than HJ16 against 15 viruses, than VRC01 against 8 viruses, and than
CH103 against 6 viruses (Fig 2D). Its overall breadth of activity across the clade B virus panel
was 70% (S4 Table).
179NC75 binds Env by an HJ16-type mechanism
To map the epitope targeted by 179NC75 and its clonal variants, we performed a series of ELI-
SAs. All members of the 179NC75 clonal family bound to HIV-1YU2 gp120, gp140 foldon [34]
and 2CC core [22] proteins (S2 Fig). In a competition ELISA, soluble CD4 (sCD4) and most
CD4bs antibodies competed with 179NC75 for binding to gp120YU2, whereas PGT121,
PGT128 and 10–1074 did not (Fig 3A upper and lower panels). The 8ANC195 bNAb, which
binds an epitope adjacent to the CD4bs [7,35], inhibited 179NC75 binding by ~ 50% (Fig 3A,
lower panel). We conclude that the 179NC75 epitope is proximal to the CD4bs.
We next tested how different mutations in the CD4bs affected 179NC75 binding. The
D368R single mutation was not sufficient to affect the gp120-binding of 179NC75 family mem-
bers, but the D368R and N280Y double mutation substantially impaired their binding. In con-
trast, VRC01 is sensitive to the single D368R substitution (Fig 3B, right upper and lower
panels).
The Asn276 glycan site is important for the binding of two different bNAbs: the CD4bs
antibody HJ16 [36] and the gp120-gp41 specific antibody 8ANC195 [7,35]. The 8ANC195 epi-
tope lies outside the CD4bs and this antibody binds Env in the presence of CD4 [7,35]. Since
HJ16 strongly inhibited 179NC75 binding (Fig 3A, upper panel) and 8ANC195 did so weakly
(Fig 3A, lower panel), we assessed whether the binding of 179NC75 family members was
affected by the N276D substitution and found that it had a profound impact (Fig 3B, lower left
panel). In contrast, the N276D change had no effect on VRC01 binding, as previously reported
[37] (Fig 3B). When monomeric gp120s from both YU2 and the clade A/E virus 93TH057 [38]
were treated with EndoH, a glycosidase that removes N-linked oligomannose glycans, the bind-
ing of 179NC75 and its clonal variants was completely abolished (Fig 3C). To further probe the
nature of the glycan-dependency of 179NC75, we tested binding of the Fab to BG505
SOSIP.664 trimers, (fully glycosylated, cleaved, native-like, soluble trimers [25]) produced in
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HEK293-6E cells in the presence and in the absence of the mannosidase I inhibitor kifunen-
sine. HEK293-6E cells fully process glycans resulting in a mixture of complex-type and high-
mannose N-glycans, while HEK293-6E cells treated with kifunensine, produce protein contain-
ing only high-mannose N-glycans. We observed that 179NC75 binds to BG505 SOSIP.664 tri-
mer with processed glycans with a KD of ~90 nM, (S3 Fig) but cannot bind to trimers
containing only high mannose glycans (S3 Fig, S6 Table). Hence, we conclude that 179NC75 is
a glycan-dependent antibody that binds to the CD4bs in a way that involves the Asn276 residue
and depends on the presence of complex glycans. In these respects, its epitope is similar to that
of the HJ16 CD4bs bNAb.
We compared the neutralization potencies of 179NC75 to the ones of HJ16 [18]. For the 53
Tier-2 viruses that were tested against both HJ16 and 179NC75, 179NC75 neutralized more
viruses than HJ16 (26 compared to 19), and was 20-fold more potent (IC50 of 0.118 μg/ml com-
pared to 2.326 μg/ml) (Fig 3D).
Predicted germline variant of 179NC75 binds to BG505 SOSIP
Previous reports show that neutralizing antibodies bind BG505 SOSIP.664 trimers with higher
affinity as opposed to non-neutralizing antibodies [25]. Therefore, as expected, the more potent
variants of the 179NC75 clone, 179NC75 and 179NC1055, bound strongly to BG505
SOSIP.664-D7324 trimers in capture ELISA, while 179NC65 and 179NC21 bound weakly or
not at all, respectively (S4 Fig).
Most predicted germline versions of CD4bs antibodies are unable to bind Env antigens [7].
To test whether the germline version of 179NC75 could bind the BG505 SOSIP.664-D7324 tri-
mers, and assess the role of CDRH3 in trimer binding, we generated a germline version of
179NC75 (179NC75gl). The predicted germline version of the antibody was made as previ-
ously described by reverting the V and J segments of the heavy and light chains to their pre-
dicted germline sequences, while retaining the CDRH3 sequence as found in the mutated
antibody [7,39,40]. For comparison, we used the previously published predicted germline ver-
sions of VRC01 [39,40], 3BNC60 [7], 1NC9 [7], CH103 [19] and HJ16 (constructed in the
course of this study). Although all of the above mature CD4bs bNAbs bound the BG505
SOSIP.664-D7324 trimers, the only predicted germline antibody able to do so was 179NC75gl
(Fig 4). An implication is that 179NC75 binding principally involves contacts made by the
CDR3s, particularly the exceptionally long (24-residue) heavy chain CDR3.
In vivo activity
The loop binding, glycan-dependent CD4bs bNAbs have not been tested for their activity in
vivo. To address this issue, we treated six HIV-1YU2–infected hu-mice with 179NC75 for 5
weeks [8,29]. Monotherapy with 179NC75 resembled monotherapy with other bNAbs, in that
there was a transient decrease in viral load in most of the treated animals followed by a rapid
rebound [8,29,41] (Fig 5A and 5B). Viral env genes were cloned and sequenced from the day-
28 plasma of 179NC75-treated mice, a time point where viremia had universally rebounded to
levels similar to the day-0 value. Two types of mutations were consistently observed, both
Fig 2. 179NC75 clonal family variants. (A) Dendrogram showing heavy chain amino acid sequence alignment of the different 179NC75 variants to their
closest germline IGVH3-21. (B) The same plot as in (A), but for the light chains. The heavy and light chains of the variants that were expressed and tested for
neutralization are marked with red squares. (C) Neutralization IC50 values for 179NC75 and five variants against an expanded panel of Tier-2 viruses. The
phylogenetic relationship, based on heavy chain sequences, between the six variants are shown on the bottom of the table (D) The plot compares the IC50
values for 179NC75 (red circles) and four well characterized CD4bs bNAbs (VRC01 –green diamonds, b12 –yellow squares, CH103 –blue diamonds and
HJ16 –white circles) against a panel of 26 clade B Tier-2 viruses.
doi:10.1371/journal.ppat.1005238.g002
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proximal to the CD4bs: the first eliminated the glycan-site at position N276; the second
involved residues G459 or K460 (Fig 5C). In total, 13 sequences had only a mutation affecting
the N276 glycan site, whereas 8 contained mutations in the region near position 460 and 7
sequences contained mutations in both regions (Fig 5C and 5D). In all mice the rebounding
viruses carried at least one of these mutations. In mouse 1107 mutations in both areas were
observed, resulting in the loss of the N276 glycan but the introduction of a potential N-linked
glycosylation site (PNGS) at position 460 (Fig 5C). To confirm that the most commonly
observed mutations did confer resistance, HIV-1YU2 Env-pseudoviruses containing one or
both of the N276D and K460N substitutions were tested for their sensitivity to 179NC75. All
three of the virus mutants were found to be 179NC75-resistant (Fig 5E). We also tested the
HIVYU2 N280Y, N332K, N160K and G459D virus mutants. As expected, and consistent with
the ELISA data, the N280Y substitution conferred complete resistance to 179NC75, while the
N332K and N160K changes had no effect. The G459D mutant was also 179NC75-sensitive
Fig 3. Epitopemapping of 179NC75 variants by ELISA. (A) Competition ELISA. The plots show the binding of biotinylated 179NC75 (constant
concentration of 2 μg/ml) to gp120 in the presence of increasing concentrations of different bNAbs. The black bold line represents 179NC75 binding in the
absence of a competitor antibody, the red bold line shows auto-competition by non-biotinylated 179NC75. Upper panel: Competition by CD4bs bNAbs; lower
panel competition by non-CD4bs bNAbs. (B) Binding of 179NC75 (red circles), 179NC65 (red triangles) and 179NC1055 (red diamonds) antibodies to the
wild-type YU2 gp120 monomer (left upper panel) and variants containing CD4bs-related mutations (D368R+N280Y, right upper panel; D368R, right lower
panel; N276D, left lower panel), VRC01 and PGT121 served as control antibodies. (C) 179NC75, 179NC65 and 179NC1055 binding to gp120 monomers
from YU2 (clade B) and 93TH057 (clade A/E) before and after deglycosylation with EndoH. VRC01 was used as a control antibody in the experiment
involving the YU2 gp120s. (D) Comparison between the neutralizing activity (IC50) of 179NC75 and HJ16 against a cross-clade virus panel of Tier-2 viruses.
doi:10.1371/journal.ppat.1005238.g003
Fig 4. Mature versus predicted germline antibody binding to BG505 SOSIP.664-D7324 trimers in
ELISA. (A) and (B) Binding of mutated CD4bs bNAbs (“MATURE”) and their reverted germline versions
(“GERMLINE”) to BG505 SOSIP,664-D7324 trimers. The MGO.053 antibody [48] was used as a negative
control.
doi:10.1371/journal.ppat.1005238.g004
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(Fig 5E). We conclude, that 179NC75 is a potent neutralizing antibody that exerts selection
pressure on HIV-1YU2 in vivo and drives the emergence of resistant viruses with sequence
changes proximal to the CD4bs.
Autologous viral selection by 179NC75
To test whether 179NC75 exerted selective pressure on the autologous virus found in subject
EB179, we cloned env genes from the donor’s T cells obtained at the time of the leukapheresis.
All nine gp120 sequences obtained contained Asn at position 460, introducing a PNGS at that
position in eight of the nine sequences (Fig 6A–6C). Five sequences contained an Asn-Gly-Thr
insertion immediately N-terminal to position N460, resulting in the sequence NGTNET, and
therefore adding another PNGS to the one that was already at position 460. Five other
sequences contained the N276S mutation, eliminating the PNGS at position 276. One of the
nine sequences included both the Asn-Gly-Thr insertion at position 460 and the N276S change
(Fig 6C). Of note is that this pattern of sequence changes is highly similar to the escape muta-
tions seen in the env genes of the 179NC75-treated, HIV-1YU2-infected hu-mice (Fig 5). To test
whether the autologous virus from patient EB179 is resistant to 179NC75, we cultured the
donor’s CD4+ T cells from the same leukapheresis sample that was used for the antibody isola-
tion. Outgrown virus was then tested for neutralization in the TZM.bl assay for neutralization
by the EB179 polyclonal IgG (from the same time point), as well as by 179NC75 and other
known bNAbs including the CD4bs antibody 3BNC117 [7], the V3-stem binding antibody 10–
1074 [42] and the V1/V2 apex-binding antibody PG16 [43] (Fig 6D). As expected, the EB179
polyclonal IgG failed to neutralize the autologous virus. Amongst the two CD4bs antibodies,
the autologous virus was fourfold more resistant to 179NC75 than to 3BNC117, suggesting
that the EB179 antibody repertoire has CD4bs antibodies that differ from 3BNC117 and
VRC01-class bNAbs. Interestingly, the autologous virus was also resistant to PG16 and 10–
1074, indicating that the patient may have additional neutralizing antibodies bearing similar
specificities in his antibody repertoire. Taken together, the data imply that loop-based, glycan-
dependent CD4bs bNAbs of the 179NC75 family exert selective pressure on HIV-1 in vivo.
Discussion
The CD4bs is a highly conserved epitope on the HIV-1 Env and an important potential target
for neutralizing antibodies. Although this site evolved to avoid antibody accessibility, two
major groups of CD4bs bNAbs have been discovered [15]. The first group, exemplified by
VRC01, is VH-restricted, IGVH1-2 or IGVH1-46, with the heavy chains positioned in a
CD4-like orientation and CDRH2 making significant contacts with gp120 [6,7,15]. The
CDRL3 [7,21,44], and in some cases also CDRL1 [6], of the corresponding light chains have to
be short and compact to minimize potential interference and clashes with the glycans that sur-
round the CD4bs. The emergence of these antibodies involves many somatic hypermutations,
Fig 5. Hu-mice treatment with 179NC75. (A) Viral loads in six HIV-1YU2-infected hu-mice when 179NC75 was administered two weeks post-infection (day-
0). The red line indicates the geometric mean value. (B) Log change in viral loads in each mouse compared to the day 0 value. (C) Left panel: each horizontal
gray bar represents the sequence of a single gp120 clone aligned to HIV-1YU2. Synonymous and non-synonymous nucleotide substitutions are indicated in
green and red, respectively. Sequences are grouped by the mouse from which they were obtained (center), indicated by the vertical black bars. An expanded
view of the boxed areas is shown in the right panel. (D) Pie chart showing the recurrent mutations in gp120 compared to the wild-type HIV-1YU2 sequence.
The number in the center of the pie denotes the total number of sequences cloned; the blue, red and purple slices represent the most consistently mutated
areas in gp120, i.e., around residues 276 and 460, respectively. The sizes of the slices are proportional to the number of sequences that carried mutations.
The original residue, as found in HIV-1YU2, is indicated on the outside of the pie chart, the various mutations in the cloned sequences are shown on the inside
of the chart. “Δ” denotes a deletion of the residue. The purple slice indicates the presence of both the blue (276-area) and red (460-area) mutations. (E) The
table shows IC50 values for 179NC75 neutralization of the wild-type HIV-1YU2 pseudovirus and mutants containing either the gp120 changes most frequently
observed after treatment or other mutations that serve as comparators.
doi:10.1371/journal.ppat.1005238.g005
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some of which are in the framework regions [45]. The second group of CD4bs bNAbs, which
includes b12 and HJ16, is far more heterogeneous. These antibodies bind to gp120 via a
CDRH3-dominated, loop based mechanism [15]. As might be expected, members of this
group of CD4bs bNAbs arise from different VH segments and carry fewer somatic mutations
[17–19]. The new antibody described in this study, 179NC75, is a loop binder that is closely
related to HJ16. Similarly to HJ16, its Env-binding and virus-neutralizing activities are depen-
dent on the N276 glycan [36]. Consistent with the CDRH3 loop-based mechanism of recogni-
tion that was described for antibodies that are not VH-restricted [15], when we generated the
predicted germline version of 179NC75, where all mutations were reverted but the CDRH3
Fig 6. Autologous viruses from EB179. (A) Horizontal gray bars represents single gp120 sequences amplified and cloned from patient sera. The vertical
rectangles show areas where recurrent mutations were found. (B) Expanded view of the most consistently mutated areas. (C) Pie chart comparing the
recurrent mutations in gp120s from the EB179 autologous virus and HIV-1YU2. The number in the center of the pie denotes the total number of sequences
cloned, and the sizes of slices are proportional to the number of sequences that carried the mutations; the color coding is same as used in Fig 5D. (D) The
table shows IC50 values for the neutralization of the EB179 autologous culture virus by the autologous patient polyclonal IgG, as well as 179NC75, 3BNC117,
10–1074 and PG16 bNAbs.
doi:10.1371/journal.ppat.1005238.g006
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was retained, the antibody bound to BG505 SOSIP.664 trimers. This could indicate that any
residual mutations present in the CDR3s of the reverted antibody might allow binding. Inter-
estingly, the germline version of HJ16 also had some binding to BG505 SOSIP.664 trimers
(Fig 4), however this binding was lower that the one of 179NC75, which could be attributed to
a shorter CDRH3 (19 versus 24 residues).
Serum antibodies that are CD4bs-specific and N276-dependent have been described in
HIV-1-infected individuals in two separate studies [32,46]. In the first study, an HJ16-type of
CD4bs antibody response was found to be part of the second wave of serum neutralization in
the CAP257 patient [46]. Viruses cloned from CAP257 after the emergence of these CD4bs
antibodies carried an N276D or T278A mutation that were considered to be responses to anti-
body selection pressure [46]. In a second study, serum from individual VC1004 contained
CD4bs-targeted NAbs that were sensitive to the N276D substitution but not D368R [47]. How-
ever, as the antibodies responsible for the serum activity were not cloned in either study much
of what we know about the in vivo activity of these N276-dependent class of CD4bs antibodies
is inferential. Our 179NC75 therapy experiments in HIV-1–infected hu-mice demonstrate that
escape variants contain very similar, and sometimes identical, mutations to ones present in the
autologous virus isolated from the infected human from whom the 179NC75 antibody was also
derived. We conclude that the CDRH3-dominted N276-dependent CD4bs antibodies are effec-
tive at suppressing viremia in vivo and thence driving the emergence of escape variants.
Supporting Information
S1 Fig. Number of mutations in V-region in the 2CC core-sorted antibodies. The number
of nucleotide mutations in sequences that are part of a clonal family (“clonally related”) is com-
pared to sequences that appeared only once (“singles”). (B) The same analysis as in (A), but for
the light chains.
(PDF)
S2 Fig. Binding of 179NC75 and its variants to soluble Env proteins in ELISA. Each of the
four variants, 179NC21, 65, 75 and 1055, was tested for binding to 2CC core, monomeric
gp120 and gp140 foldon proteins. VRC01 and PGT121 were used as controls.
(PDF)
S3 Fig. SPR binding studies. The upper panel shows sensograms from SPR binding studies.
BG505 SOSIP.664 trimers expressed in HEK203-6E cells (resulting in a mixture of high-man-
nose and complex N-glycans) or HEK203-6E cells treated with kifunensine (resulting in high-
mannose N-glycans only) were immobilized by injecting them over the indicated capture anti-
bodies. 179NC75 Fab was then injected over captured trimers as a 4-fold dilution series with a
top concentration of 500 nM. Residuals for a 1:1 binding model fit to the sensorgram data are
shown below each sensogram from which KD values were obtained (see table in the lower
panel of the figure). The weak binding responses to high-mannose-only BG505 SOSIP.664 tri-
mers (bottom panel) could not be fit to a binding model. The table in the lower panel sum-
merizes the affinities of 179NC75 Fab for BG505 SOSIP.664 derived by surface plasmon
resonance (SPR). On/off rates (ka/kd) and binding constants (KD (M)) were calculated by
kinetic analyses after subtraction of backgrounds using a 1:1 binding model using the Biacore
T200 Evaluation software.
(PDF)
S4 Fig. Binding of 179NC75 and its variants to BG505 SOSIP,664-D7324 trimers in
ELISA. Each of the four variants, 179NC21, 65, 75 and 1055, was tested for their binding to
BG505 SOSIP.664-D7324 trimers. The quaternary structure-influenced bNAbs PGT145 and
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